Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bristol-Myers Squibb Co (NYSE:BMY)

71.12
BATS BZX Real-Time Price
As of 9:58am ET
 +0.80 / +1.14%
Today’s Change
51.82
Today|||52-Week Range
75.12
+3.39%
Year-to-Date
BMY Regular Dividend: BMY will begin trading ex-dividend on 06/29/16 with a $0.38 dividend payable to shareholders of record as of 07/01/16.
Cramer: Here's What's Behind the Horrible Politics of Brexit
9:53am / TheStreet.com - Paid Partner Content
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Jun 24 / Zacks.com - Paid Partner Content
Puma (PBYI) Submits Neratinib Marketing Application in EU
9:39am / Zacks.com - Paid Partner Content
Why Investors Are Paying a Premium for These 3 Drugmakers
Jun 24 / MotleyFool.com - Paid Partner Content
GW Pharmaceuticals Stock Up on Positive Epidiolex Data
9:08am / Zacks.com - Paid Partner Content
Incyte Reports Epacadostat Combination Study Initiation
Jun 23 / Zacks.com - Paid Partner Content
New Strong Buy Stocks for June 28th
8:30am / Zacks.com - Paid Partner Content
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Jun 22 / Zacks.com - Paid Partner Content
Mylan Launches Generic Version of Glaxo's Avodart in U.S.
Jun 27 / Zacks.com - Paid Partner Content
Cramer: Let's Put Brexit in Its Historic Context
Jun 22 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close70.32
Today’s open70.95
Day’s range70.70 - 71.24
Volume25,024
Average volume (3 months)6,078,050
Market cap$117.4B
Dividend yield2.14%
Data as of 9:58am ET, 06/28/2016

Growth & Valuation

Earnings growth (last year)-22.50%
Earnings growth (this year)+25.84%
Earnings growth (next 5 years)+21.20%
Revenue growth (last year)+4.29%
P/E ratio75.7
Price/Sales6.97
Price/Book8.19

Competitors

 Today’s
change
Today’s
% change
SNYSanofi+1.19+3.04%
NVONovo Nordisk+0.99+1.94%
GSKGlaxoSmithKline+0.86+2.14%
ABBVAbbVie+0.59+1.01%
Data as of 9:58am ET, 06/28/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)$0.66
Annual revenue (last year)$16.6B
Annual profit (last year)$1.6B
Net profit margin9.45%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chief Executive Officer &
Director
Giovanni Caforio
Chief Financial Officer &
Executive Vice President
Charles A. Bancroft
Corporate headquarters
New York, New York

Forecasts

Partner Offers

Search for Jobs